Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
NMDA Receptors (NMDARs) play key roles in synaptic physiology and NMDAR hypofunction has been implicated in various neurological conditions. In recent years an increasing number of positive allosteric modulators (PAMs) of NMDARs have been discovered and characterized. These diverse PAM classes vary not only in their binding sites and GluN2 subunit selectivity profiles, but also in the nature of their impacts on channel function. Major differences exist in the degree of slowing of channel deactivation and shifting of apparent agonist affinity between different classes of PAMs. Here we review the diverse modes of potentiation by the currently known classes of NMDAR PAMs and discuss the potential consequences of different types of potentiation in terms of desirable and undesirable effects on brain function. This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 2×
“…ligand-gated ionotropic glutamate receptors exist that are defined by the pharmacology of their Glu binding sites: alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (AMPARs), kainate receptors (KARs), and N-methyl-Daspartate (NMDA) receptors (NMDARs) (Traynelis et al., 2010).”
BackgroundMonyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 2×
“Four types of GluN2 subunits exit that have distinct spatial and temporal expression patterns in the CNS: GluN2A, GluN2B, GluN2C, and GluN2D (Akazawa et al., 1994; Laurie and Seeburg, 1994; Monyer et al., 1994; Standaert et al., 1994; Watanabe et al., 1992, 1994).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 2×
“Dysfunction of NMDAR signaling has been implicated in a variety of neurological and psychiatric disorders and thus there is growing interest in developing novel drugs that target these receptors (Paoletti et al., 2013; Soto et al., 2014; Zhou and Sheng, 2013).”
BackgroundSynaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · cited 2×
“Hypothesis for the damaging effects of GluN2B NMDAR over-activation include preferential coupling of GluN2B-containing NMDARs to signaling pathways involved in cell death, and/or the preferential extrasynaptic location of these receptors (Hardingham and Bading, 2010; Martel et al., 2012; Zhou and Sheng, 2013).”
BackgroundHomayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“…in interneurons could explain the ability of systemic CIQ treatment to oppose the behavioral impacts of treatment with the psychotomimetic NMDAR pore blocker MK-801 (Suryavanshi et al., 2014), which can alter circuit function via reduction of interneuron activation (Homayoun and Moghaddam, 2007).”
BackgroundVerret, L., Mann, E. O., Hang, G. B., Barth, A. M. I., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A. C., Mody, I., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.046 · Cited by 1,216
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938 · cited 2×
“Consistent with this idea, NMDAR inhibition leads to decreased expression of PV within PV interneurons (Behrens et al., 2007; Kinney et al., 2006), and decreased PV levels are observed in post-mortem schizophrenia brain samples (Hashimoto et al., 2003).”
BackgroundLiu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, M., Craig, A. M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0116-07.2007 · Cited by 773 · cited 2×
“…diheteromers compared to GluN1/2A/2B triheteromers (Hansen et al., 2014; Hatton and Paoletti, 2005; Stroebel et al., 2014), has implicated GluN2B-containing NMDARs in mediating excitotoxic cell damage and death (Costa et al., 2012; Liu et al., 2007; Ronicke et al., 2011; Zeron et al., 2002).”
BackgroundPostnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., & Nakazawa, K. (2010) · Nature Neuroscience · doi:10.1038/nn.2447 · Cited by 752
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585 · cited 2×
“Consistent with this idea, NMDAR inhibition leads to decreased expression of PV within PV interneurons (Behrens et al., 2007; Kinney et al., 2006), and decreased PV levels are observed in post-mortem schizophrenia brain samples (Hashimoto et al., 2003).”
BackgroundGonzalez-Burgos, G., & Lewis, D. A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs010 · Cited by 478 · cited 5×
“While LTP enhancement could be desirable in some disease contexts, in theory PAMs that could selectively enhance interneuron function could also be beneficial in the context of diseases associated with interneuron hypofunction, which as discussed include schizophrenia, epilepsy and Alzheimer's disease (Gonzalez-Burgos…”
BackgroundInfluentialKinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4722-05.2006 · Cited by 329 · cited 2×
“Consistent with this idea, NMDAR inhibition leads to decreased expression of PV within PV interneurons (Behrens et al., 2007; Kinney et al., 2006), and decreased PV levels are observed in post-mortem schizophrenia brain samples (Hashimoto et al., 2003).”
BackgroundDistinct Roles of NR2A and NR2B Cytoplasmic Tails in Long-Term Potentiation
Foster, K. A., McLaughlin, N., Edbauer, D., Phillips, M., Bolton, A., Constantine-Paton, M., & Sheng, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4022-09.2010 · Cited by 219
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208 · cited 1×
“Unfortunately, recent clinical trials of selective GlyT1 inhibitors have failed to show efficacy in schizophrenia patients, suggesting that GlyT1 transporters may not play a critical role in setting Gly levels at the specific synapses that are important for schizophrenia (Balu and Coyle, 2015).”
BackgroundBitanihirwe, B., Lim, M., Kelley, J., Kaneko, T., & Woo, T. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-71 · Cited by 137 · cited 1×
“Further studies have found reduced expression of NMDARs (in particular the GluN2A subunit) in parvalbumin (PV)-expressing interneurons in postmortem samples of schizophrenia patients (Akbarian et al., 1996; Bitanihirwe et al., 2009).”
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
“GluN2 LBDs contain the glutamate binding site, while GluN1 (or GluN3) LBDs contain the Glycine/Dserine coagonist binding site (Hackos and Hanson, 2017).”
BackgroundRegulation of NMDA glutamate receptor functions by the GluN2 subunits
Vieira, M., Yong, X. L. H., Roche, K. W., & Anggono, V. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14970 · Cited by 151
“…with differences in sensitivity to extracellular Zn2+, protons, spermine and other pharmacological agonists, antagonists and allosteric modulators, which are described in detail in several excellent reviews (Hansen et al., 2018; Traynelis et al., 2010; Zhu & Paoletti, 2015; Hackos & Hanson, 2017).”
BackgroundNeurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders
Ratner, M. H., Kumaresan, V., & Farb, D. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00169 · Cited by 96
Metadata
- Authors
- Hackos, D. H., & Hanson, J. E.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 112
- Issue
- Pt A
- Pages
- 34-45
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2486908111
- Cited by
- 93
- References
- 19
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.